The cells that make up cancerous brain tumors are extremely varied and sometimes create unique three-dimensional shapes. As ...

A new targeted drug for low-grade glioma brain cancer was approved the FDA—treating the IDH-mutant gene discovered 16 years ...

Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first ...

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food ...

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 ...

The newly FDA-approved brain cancer therapy Voranigo (vorasidenib) has its roots in North Carolina. It is the product of research by Duke University's Darell Bigner and Bert Vogelstein of Johns ...

Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval. "Today's approval of Voranigo is an enormous leap forward in ...

The primary endpoint was progression free survival (PFS) as evaluated by a blinded independent review committee per modified Response Assessment in Neuro-Oncology for Low Grade Glioma (RANO-LGG ...

Of note, Voranigo marks the first FDA-approved systemic therapy for this population of patients with IDH 1 and 2 mutations, ...

Diffuse gliomas with IDH mutations represent the most common malignant primary brain tumors diagnosed in adults younger than 50 years of age. They are not curable with current therapies and ...